3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Publication
, Journal Article
Sanders, DB
Published in: Ann N Y Acad Sci
May 13, 1998
Duke Scholars
Published In
Ann N Y Acad Sci
DOI
ISSN
0077-8923
Publication Date
May 13, 1998
Volume
841
Start / End Page
811 / 816
Location
United States
Related Subject Headings
- Time Factors
- Potassium Channels
- Myasthenia Gravis
- Mice
- Lambert-Eaton Myasthenic Syndrome
- Humans
- General Science & Technology
- Follow-Up Studies
- Animals
- Amifampridine
Citation
APA
Chicago
ICMJE
MLA
NLM
Sanders, D. B. (1998). 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Ann N Y Acad Sci, 841, 811–816. https://doi.org/10.1111/j.1749-6632.1998.tb11022.x
Sanders, D. B. “3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).” Ann N Y Acad Sci 841 (May 13, 1998): 811–16. https://doi.org/10.1111/j.1749-6632.1998.tb11022.x.
Sanders DB. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Ann N Y Acad Sci. 1998 May 13;841:811–6.
Sanders, D. B. “3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).” Ann N Y Acad Sci, vol. 841, May 1998, pp. 811–16. Pubmed, doi:10.1111/j.1749-6632.1998.tb11022.x.
Sanders DB. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Ann N Y Acad Sci. 1998 May 13;841:811–816.
Published In
Ann N Y Acad Sci
DOI
ISSN
0077-8923
Publication Date
May 13, 1998
Volume
841
Start / End Page
811 / 816
Location
United States
Related Subject Headings
- Time Factors
- Potassium Channels
- Myasthenia Gravis
- Mice
- Lambert-Eaton Myasthenic Syndrome
- Humans
- General Science & Technology
- Follow-Up Studies
- Animals
- Amifampridine